The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
The Biden administration recently launched the Global Health Security Strategy, a new effort to improve the country’s ability to prevent, detect, and respond to the spread of infectious diseases, according to NPR. With this new strategy, the White House strives to make the US better prepared for future pandemics, outbreaks, and biological threats, regardless of where they occur. Consequently, the US will also be expanding its health security partnerships to 50 countries worldwide; the US will help these countries improve their abilities to identify and respond to diseases, including improved testing, surveillance, lab capacity, and immunizations. However, some experts worry the new strategy does not go far enough and financial realities will limit its impact. The new plan, which is based on lessons learned from the COVID-19 pandemic, will roll out over 5 years.
Lawmakers zeroed in on the risks of massive consolidation in health care on Tuesday during the first congressional hearing on the Change Healthcare hack, according to Axios. Lawmakers expressed concerns about the impact of mergers forming health care giants like UnitedHealth Group, Change Healthcare’s parent company, after the late February attack against Change Healthcare, the country’s largest medical claims processor, halted payments and crippled operations at some hospitals and clinics. During the hearing, several lawmakers expressed frustration that UnitedHealth did not send a representative or provide answers to key questions; UnitedHealth CEO Andrew Witty is expected to testify soon before the Senate Finance Committee. Although Congress is in the early stages of forming a possible response, lawmakers’ comments suggested the possibility of crackdowns on vertical mergers that have allowed health care companies to expand their reach.
The FDA recently announced the recall of HeartMate II and HeartMate 3, a pair of heart devices linked to hundreds of injuries and at least 14 deaths, according to KFF Health News. The recalled devices are mechanical pumps that help the heart pump blood when it cannot do so on its own; the devices are implanted in patients with end-stage heart failure. The recall affects nearly 14,000 devices. According to the recall notice, the devices can cause a buildup of biological material that reduces the ability to help the heart circulate blood and keep patients alive; the buildup accumulates gradually and can appear 2 years or more after a device is implanted. The FDA advised doctors to watch for low-flow alarms on the devices and, if an obstruction is present, to either monitor the patient or perform surgery to implant a stent, release the blockage, or replace the pump. Despite the recall, the devices are not currently being removed from the market.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More